Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity

Authors: Hyejin Jeon, Jong-Heon Kim, Jae-Hong Kim, Won-Ha Lee, Myung-Shik Lee, Kyoungho Suk

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Background

Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of urokinase type plasminogen activators (uPA) and tissue type plasminogen activators (tPA), which mediate fibrinolysis. PAI-1 is also involved in the innate immunity by regulating cell migration and phagocytosis. However, little is known about the role of PAI-1 in the central nervous system.

Methods

In this study, we identified PAI-1 in the culture medium of mouse mixed glial cells by liquid chromatography and tandem mass spectrometry. Secretion of PAI-1 from glial cultures was detected by ELISA and western blotting analysis. Cell migration was evaluated by in vitro scratch-wound healing assay or Boyden chamber assay and an in vivo stab wound injury model. Phagocytic activity was measured by uptake of zymosan particles.

Results

The levels of PAI-1 mRNA and protein expression were increased by lipopolysaccharide and interferon-γ stimulation in both microglia and astrocytes. PAI-1 promoted the migration of microglial cells in culture via the low-density lipoprotein receptor-related protein (LRP) 1/Janus kinase (JAK)/signal transducer and activator of transcription (STAT)1 axis. PAI-1 also increased microglial migration in vivo when injected into mouse brain. PAI-1-mediated microglial migration was independent of protease inhibition, because an R346A mutant of PAI-1 with impaired PA inhibitory activity also promoted microglial migration. Moreover, PAI-1 was able to modulate microglial phagocytic activity. PAI-1 inhibited microglial engulfment of zymosan particles in a vitronectin- and Toll-like receptor 2/6-dependent manner.

Conclusion

Our results indicate that glia-derived PAI-1 may regulate microglial migration and phagocytosis in an autocrine or paracrine manner. This may have important implications in the regulation of brain microglial activities in health and disease.
Literature
1.
Popovich PG, Longbrake EE: Can the immune system be harnessed to repair the CNS? Nat Rev Neurosci 2008, 9:481–493.PubMedCrossRef
2.
3.
Lafon-Cazal M, Adjali O, Galeotti N, Poncet J, Jouin P, Homburger V, Bockaert J, Marin P: Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome. J Biol Chem 2003, 278:24438–24448.PubMedCrossRef
4.
Keene SD, Greco TM, Parastatidis I, Lee SH, Hughes EG, Balice-Gordon RJ, Speicher DW, Ischiropoulos H: Mass spectrometric and computational analysis of cytokine-induced alterations in the astrocyte secretome. Proteomics 2009, 9:768–782.PubMedPubMedCentralCrossRef
5.
Moore NH, Costa LG, Shaffer SA, Goodlett DR, Guizzetti M: Shotgun proteomics implicates extracellular matrix proteins and protease systems in neuronal development induced by astrocyte cholinergic stimulation. J Neurochem 2009, 108:891–908.PubMedCrossRef
6.
Kim S, Ock J, Kim AK, Lee HW, Cho JY, Kim DR, Park JY, Suk K: Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J Neurochem 2007, 103:2640–2650.PubMed
7.
Liu J, Hong Z, Ding J, Liu J, Zhang J, Chen S: Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies. J Proteome Res 2008, 7:2033–2049.PubMedCrossRef
8.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57–69.PubMedCrossRef
9.
Garden GA, Moller T: Microglia biology in health and disease. J Neuroimmune Pharmacol 2006, 1:127–137.PubMedCrossRef
10.
11.
Mallat M, Marin-Teva JL, Cheret C: Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 2005, 15:101–107.PubMedCrossRef
12.
Woo MS, Park JS, Choi IY, Kim WK, Kim HS: Inhibition of MMP-3 or −9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 2008, 106:770–780.PubMedCrossRef
13.
Magnus T, Chan A, Savill J, Toyka KV, Gold R: Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002, 130:1–9.PubMedCrossRef
14.
Orr CF, Rowe DB, Halliday GM: An inflammatory review of Parkinson’s disease. Prog Neurobiol 2002, 68:325–340.PubMedCrossRef
15.
Perry VH, Nicoll JA, Holmes C: Microglia in neurodegenerative disease. Nat Rev Neurol 2010, 6:193–201.PubMedCrossRef
16.
Wersinger C, Sidhu A: An inflammatory pathomechanism for Parkinson’s disease? Curr Med Chem 2006, 13:591–602.PubMedCrossRef
17.
Eikelenboom P, Bate C, Van Gool WA, Hoozemans JJ, Rozemuller JM, Veerhuis R, Williams A: Neuroinflammation in Alzheimer’s disease and prion disease. Glia 2002, 40:232–239.PubMedCrossRef
18.
19.
20.
Stence N, Waite M, Dailey ME: Dynamics of microglial activation: a confocal time-lapse analysis in hippocampal slices. Glia 2001, 33:256–266.PubMedCrossRef
21.
Ha H, Oh EY, Lee HB: The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 2009, 5:203–211.PubMedCrossRef
22.
Gabriel C, Ali C, Lesne S, Fernandez-Monreal M, Docagne F, Plawinski L, MacKenzie ET, Buisson A, Vivien D: Transforming growth factor alpha-induced expression of type 1 plasminogen activator inhibitor in astrocytes rescues neurons from excitotoxicity. FASEB J 2003, 17:277–279.PubMed
23.
Hultman K, Blomstrand F, Nilsson M, Wilhelmsson U, Malmgren K, Pekny M, Kousted T, Jern C, Tjarnlund-Wolf A: Expression of plasminogen activator inhibitor-1 and protease nexin-1 in human astrocytes: Response to injury-related factors. J Neurosci Res 2010, 88:2441–2449.PubMed
24.
Myohanen H, Vaheri A: Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004, 61:2840–2858.PubMedCrossRef
25.
Pepper MS, Rosnoblet C, Di Sanza C, Kruithof EK: Synergistic induction of t-PA by vascular endothelial growth factor and basic fibroblast growth factor and localization of t-PA to Weibel-Palade bodies in bovine microvascular endothelial cells. Thromb Haemost 2001, 86:702–709.PubMed
26.
Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003, 160:781–791.PubMedPubMedCentralCrossRef
27.
Park YJ, Liu G, Lorne EF, Zhao X, Wang J, Tsuruta Y, Zmijewski J, Abraham E: PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci U S A 2008, 105:11784–11789.PubMedPubMedCentralCrossRef
28.
Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996, 383:441–443.PubMedCrossRef
29.
Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996, 134:1563–1571.PubMedCrossRef
30.
Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA: Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997, 232:420–429.PubMedCrossRef
31.
Kirchheimer JC, Binder BR, Remold HG: Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue. J Immunol 1990, 145:1518–1522.PubMed
32.
Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ: How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003, 10:541–544.PubMedCrossRef
33.
Kamikubo Y, Neels JG, Degryse B: Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. Int J Biochem Cell Biol 2009, 41:578–585.PubMedCrossRef
34.
Degryse B, Sier CF, Resnati M, Conese M, Blasi F: PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett 2001, 505:249–254.PubMedCrossRef
35.
Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ: The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004, 279:22595–22604.PubMedCrossRef
36.
Harrison BH: Intercellular junctions in the developing mammalian thymus. Anat Histol Embryol 1977, 6:325–331.PubMedCrossRef
37.
Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L: Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006, 25:1860–1870.PubMedPubMedCentralCrossRef
38.
Gveric D, Herrera B, Petzold A, Lawrence DA, Cuzner ML: Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003, 126:1590–1598.PubMedCrossRef
39.
Jacobsen JS, Comery TA, Martone RL, Elokdah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzales C, Xu J, Zhou H, Atchison K, Wagner E, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN: Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 2008, 105:8754–8759.PubMedPubMedCentralCrossRef
40.
Muracciole X, Romain S, Dufour H, Palmari J, Chinot O, Ouafik L, Grisoli F, Branger DF, Martin PM: PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int J Radiat Oncol Biol Phys 2002, 52:592–598.PubMedCrossRef
41.
Nagai N, Suzuki Y, Van Hoef B, Lijnen HR, Collen D: Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J Thromb Haemost 2005, 3:1379–1384.PubMedCrossRef
42.
Yang D, Nemkul N, Shereen A, Jone A, Dunn RS, Lawrence DA, Lindquist D, Kuan CY: Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns. J Neurosci 2009, 29:8669–8674.PubMedPubMedCentralCrossRef
43.
Docagne F, Nicole O, Gabriel C, Fernandez-Monreal M, Lesne S, Ali C, Plawinski L, Carmeliet P, MacKenzie ET, Buisson A, Vivien D: Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis. Mol Cell Neurosci 2002, 21:634–644.PubMedCrossRef
44.
Simon D, Martin-Bermejo MJ, Gallego-Hernandez MT, Pastrana E, Garcia-Escudero V, Garcia-Gomez A, Lim F, Diaz-Nido J, Avila J, Moreno-Flores MT: Expression of plasminogen activator inhibitor-1 by olfactory ensheathing glia promotes axonal regeneration. Glia 2011, 59:1458–1471.PubMedCrossRef
45.
Xu Z, Balsara RD, Gorlatova NV, Lawrence DA, Castellino FJ, Ploplis VA: Conservation of critical functional domains in murine plasminogen activator inhibitor-1. J Biol Chem 2004, 279:17914–17920.PubMedCrossRef
46.
Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D: Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994, 269:15223–15228.PubMed
47.
Lee HJ, Im H: Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies. Protein Expr Purif 2003, 31:99–107.PubMedCrossRef
48.
Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F: Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol 1990, 27:229–237.PubMedCrossRef
49.
Bocchini V, Mazzolla R, Barluzzi R, Blasi E, Sick P, Kettenmann H: An immortalized cell line expresses properties of activated microglial cells. J Neurosci Res 1992, 31:616–621.PubMedCrossRef
50.
McCarthy KD, de Vellis J: Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980, 85:890–902.PubMedCrossRef
51.
Jeon H, Lee S, Lee WH, Suk K: Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia. J Neuroimmunol 2010, 229:63–72.PubMedCrossRef
52.
Saura J, Tusell JM, Serratosa J: High-yield isolation of murine microglia by mild trypsinization. Glia 2003, 44:183–189.PubMedCrossRef
53.
Ock J, Kim S, Yi KY, Kim NJ, Han HS, Cho JY, Suk K: A novel anti-neuroinflammatory pyridylimidazole compound KR-31360. Biochem Pharmacol 2009, 87:2578–2590.
54.
Yin GN, Lee HW, Cho JY, Suk K: Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009, 1265:158–170.PubMedCrossRef
55.
Liang CC, Park AY, Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007, 2:329–333.PubMedCrossRef
56.
Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, Viani P, Sparatore B, Melloni E, Riboni L: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 2008, 87:23–33.PubMedCrossRef
57.
Auguste KI, Jin S, Uchida K, Yan D, Manley GT, Papadopoulos MC, Verkman AS: Greatly impaired migration of implanted aquaporin-4-deficient astroglial cells in mouse brain toward a site of injury. FASEB J 2007, 21:108–116.PubMedCrossRef
58.
Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG: Microglial VEGF receptor response is an integral chemotactic component in Alzheimer’s disease pathology. J Neurosci 2009, 29:3–13.PubMedCrossRef
59.
Wada M, Yoshimi K, Higo N, Ren YR, Mochizuki H, Mizuno Y, Kitazawa S: Statistical parametric mapping of immunopositive cell density. Neurosci Res 2006, 56:96–102.PubMedCrossRef
60.
Kagan JC, Roy CR: Legionella phagosomes intercept vesicular traffic from endoplasmic reticulum exit sites. Nat Cell Biol 2002, 4:945–954.CrossRefPubMed
61.
Park D, Han CZ, Elliott MR, Kinchen JM, Trampont PC, Das S, Collins S, Lysiak JJ, Hoehn KL, Ravichandran KS: Continued clearance of apoptotic cells critically depends on the phagocyte Ucp2 protein. Nature 2011, 477:220–224.PubMedPubMedCentralCrossRef
62.
Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM: Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature 2011, 472:471–475.PubMedPubMedCentralCrossRef
63.
Greenbaum D, Luscombe NM, Jansen R, Qian J, Gerstein M: Interrelating different types of genomic data, from proteome to secretome: ‘oming in on function. Genome Res 2001, 11:1463–1468.PubMedCrossRef
64.
Grimmond SM, Miranda KC, Yuan Z, Davis MJ, Hume DA, Yagi K, Tominaga N, Bono H, Hayashizaki Y, Okazaki Y, Teasdale RD: The mouse secretome: functional classification of the proteins secreted into the extracellular environment. Genome Res 2003, 13:1350–1359.PubMedPubMedCentralCrossRef
65.
Dowell JA, Johnson JA, Li L: Identification of astrocyte secreted proteins with a combination of shotgun proteomics and bioinformatics. J Proteome Res 2009, 8:4135–4143.PubMedPubMedCentralCrossRef
66.
Delcourt N, Jouin P, Poncet J, Demey E, Mauger E, Bockaert J, Marin P, Galeotti N: Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes. Mol Cell Proteomics 2005, 4:1085–1094.PubMedCrossRef
67.
Suk K: Combined analysis of the glia secretome and the CSF proteome: neuroinflammation and novel biomarkers. Expert Rev Proteomics 2010, 7:263–274.PubMedCrossRef
68.
69.
Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008, 88:887–918.PubMedPubMedCentralCrossRef
70.
Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, Mihaly J, Prager GW: Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci 2002, 17:56–61.PubMed
71.
Aaronson DS, Horvath CM: A road map for those who don’t know JAK-STAT. Science 2002, 296:1653–1655.PubMedCrossRef
72.
Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 2004, 117:1281–1283.PubMedCrossRef
73.
Kovarik P, Stoiber D, Novy M, Decker T: Stat1 combines signals derived from IFN-gamma and LPS receptors during macrophage activation. EMBO J 1998, 17:3660–3668.PubMedPubMedCentralCrossRef
74.
Huang Y, Border WA, Yu L, Zhang J, Lawrence DA, Noble NA: A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol 2008, 19:329–338.PubMedPubMedCentralCrossRef
75.
Cunningham O, Campion S, Perry VH, Murray C, Sidenius N, Docagne F, Cunningham C: Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia 2009, 57:1802–1814.PubMedPubMedCentralCrossRef
76.
Kim JW, Lee SH, Ko HM, Kwon KJ, Cho KS, Choi CS, Park JH, Kim HY, Lee J, Han SH, Ignarro LJ, Cheong JH, Kim WK, Shin CY: Biphasic regulation of tissue plasminogen activator activity in ischemic rat brain and in cultured neural cells: essential role of astrocyte-derived plasminogen activator inhibitor-1. Neurochem Int 2011, 58:423–433.PubMedCrossRef
77.
Aderem A, Underhill DM: Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999, 17:593–623.PubMedCrossRef
78.
79.
80.
Scibelli A, Roperto S, Manna L, Pavone LM, Tafuri S, Della Morte R, Staiano N: Engagement of integrins as a cellular route of invasion by bacterial pathogens. Vet J 2007, 173:482–491.PubMedCrossRef
81.
Schleef RR, Loskutoff DJ: Fibrinolytic system of vascular endothelial cells. Role of plasminogen activator inhibitors. Haemostasis 1988, 18:328–341.PubMed
82.
Brown NJ: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010, 4:315–324.PubMedCrossRef
83.
Vial D, McKeown-Longo PJ: PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the alphavbeta5 and alpha5beta1 integrins. J Cell Sci 2008, 121:1661–1670.PubMedPubMedCentralCrossRef
84.
Kreutzberg GW: Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312–318.PubMedCrossRef
85.
Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S, Krueger C, Nitsch R, Meisel A, Weber JR: Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007, 190:28–33.PubMedCrossRef
86.
Dellas C, Loskutoff DJ: Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005, 93:631–640.PubMed
87.
Garg N, Goyal N, Strawn TL, Wu J, Mann KM, Lawrence DA, Fay WP: Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost 2010, 8:1847–1854.PubMedPubMedCentralCrossRef
88.
Stahl A, Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997, 71:116–122.PubMedCrossRef
89.
Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4:923–928.PubMedCrossRef
90.
Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A: Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004, 23:6986–6990.PubMedCrossRef
91.
Marshall LJ, Ramdin LS, Brooks T, DPhil PC, Shute JK: Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003, 171:2057–2065.PubMedCrossRef
92.
Arndt PG, Young SK, Worthen GS: Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J Immunol 2005, 175:4049–4059.PubMedCrossRef
93.
Osterholzer JJ, Christensen PJ, Lama V, Horowitz JC, Hattori N, Subbotina N, Cunningham A, Lin Y, Murdock BJ, Morey RE, Olszewski MA, Lawrence DA, Simon RH, Sisson TH: EPAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 2012, doi:10.1002/path.3992..
94.
Sanes JR: Extracellular matrix molecules that influence neural development. Annu Rev Neurosci 1989, 12:491–516.PubMedCrossRef
95.
Sobel RA: The extracellular matrix in multiple sclerosis lesions. J Neuropathol Exp Neurol 1998, 57:205–217.PubMedCrossRef
96.
Lo EH, Wang X, Cuzner ML: Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 2002, 69:1–9.PubMedCrossRef
97.
Zmijewski JW, Bae HB, Deshane JS, Peterson CB, Chaplin DD, Abraham E: Inhibition of neutrophil apoptosis by PAI-1. Am J Physiol Lung Cell Mol Physiol 2011, 301:L247-L254.PubMedPubMedCentralCrossRef
98.
Gerold G, Ajaj KA, Bienert M, Laws HJ, Zychlinsky A, de Diego JL: A Toll-like receptor 2-integrin beta3 complex senses bacterial lipopeptides via vitronectin. Nat Immunol 2008, 9:761–768.PubMedCrossRef
99.
Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, Schroeder L, Aderem A: The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000, 97:13766–13771.PubMedPubMedCentralCrossRef
100.
Frasnelli ME, Tarussio D, Chobaz-Peclat V, Busso N, So A: TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther 2005, 7:R370-R379.PubMedPubMedCentralCrossRef
101.
Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M, Aderem A: The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999, 401:811–815.PubMedCrossRef
102.
Letiembre M, Echchannaoui H, Bachmann P, Ferracin F, Nieto C, Espinosa M, Landmann R: Toll-like receptor 2 deficiency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes. Infect Immun 2005, 73:8397–8401.PubMedPubMedCentralCrossRef
103.
De Taeye B, Smith LH, Vaughan DE: Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005, 5:149–154.PubMedCrossRef
104.
Skurk T, Hauner H: Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004, 28:1357–1364.PubMedCrossRef
105.
Schneider DJ: Abnormalities of coagulation, platelet function, and fibrinolysis associated with syndromes of insulin resistance. Coron Artery Dis 2005, 16:473–476.PubMedCrossRef
106.
Esposito K, Giugliano D: The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004, 14:228–232.PubMedCrossRef
107.
Metadata
Title
Plasminogen activator inhibitor type 1 regulates microglial motility and phagocytic activity
Authors
Hyejin Jeon
Jong-Heon Kim
Jae-Hong Kim
Won-Ha Lee
Myung-Shik Lee
Kyoungho Suk
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-149

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue

Research

Primary phagocytosis of viable neurons by microglia activated with LPS or Aβ is dependent on calreticulin/LRP phagocytic signalling

Research

Up-regulation of microglial cathepsin C expression and activity in lipopolysaccharide-induced neuroinflammation

Research

Temporal changes in innate immune signals in a rat model of alcohol withdrawal in emotional and cardiorespiratory homeostatic nuclei

Research

Menopause leads to elevated expression of macrophage-associated genes in the aging frontal cortex: rat and human studies identify strikingly similar changes

Research

Inhibition of P2X7 receptor ameliorates transient global cerebral ischemia/reperfusion injury via modulating inflammatory responses in the rat hippocampus

Research

Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10